---
title: "Satellos wins FDA IND clearance for forazapadin in FSHD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300018884.md"
description: "Satellos Bioscience has received FDA IND clearance to test forazapadin for facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone funding. A Phase 2 proof-of-concept trial is planned for Q4 2026."
datetime: "2026-09-24T11:03:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300018884.md)
  - [en](https://longbridge.com/en/news/300018884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300018884.md)
generator: "portal-rs"
---

# Satellos wins FDA IND clearance for forazapadin in FSHD

-   Satellos won FDA clearance for its IND to test forazapadin in facioscapulohumeral muscular dystrophy. \* FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone funding for the program. \* Phase 2 proof-of-concept trial planned for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240700PRIMZONEFULLFEED9832833) on September 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MSLE.US](https://longbridge.com/en/quote/MSLE.US.md)

## Related News & Research

- [Satellos Bioscience Participates in Guggenheim, Jefferies Healthcare Conferences](https://longbridge.com/en/news/302552043.md)
- [Stocks in Play: Satellos Bioscience Inc.](https://longbridge.com/en/news/300050214.md)
- [IREN Stock: Why Analysts Still See Over 200% Upside Despite This Week's Plunge](https://longbridge.com/en/news/302922686.md)
- [IDEAYA Reports 17.4-Month Median Survival With IDE849 in Second-Line Small Cell Lung Cancer Trial](https://longbridge.com/en/news/302858666.md)
- [Why Did Analysts Slash Bloom Energy Stock (BE) Price Targets Despite Praising Q3 Earnings Beats?](https://longbridge.com/en/news/302920834.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**